第三阶段随机的COMMODORE 1试验:克罗瓦利马布与埃奎利祖马布在补充抑制剂经验丰富的患者中,患者患有帕洛西斯马夜间血红素尿
Phillip Scheinberg1, Diego Villa Clé2, Jin Seok Kim3
1Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo, Brazil.
American journal of hematology
|June 26, 2024
概括
新的C5抑制剂克罗瓦利马布 (Crovalimab) 提供了一种方便的皮下注射选择,适用于阳性夜间血红蛋白尿症 (PNH) 患者. 康莫多1试验显示,它保持了疾病控制,具有良好的安全性,大多数患者更喜欢它而不是eculizumab.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 临床药理学 临床药理学
背景情况:
- 透性夜间血红蛋白尿 (PNH) 是一种罕见的,终身的血液疾病,其特点是补充介导的血液溶解.
- 现有的C5抑制剂需要静脉注射,造成治疗负担.
- 克罗瓦利马布是一种新型C5抑制剂,旨在进行皮下自给药.
研究的目的:
- 为了评估crovalimab与eculizumab相比的安全性和有效性,在C5抑制剂经验丰富的PNH患者中.
- 为了评估患者的偏好和crovalimab在这个人群中的益处风险概况.
主要方法:
- 第三阶段,全球性,随机的COMMODORE 1试验 (NCT04432584) 进行了测试.
- 之前接受过eculizumab治疗的89名成人PNH患者被随机分为1:1接受crovalimab或继续使用eculizumab.
- 安全是首要目标;探索性疗效终点包括输血避免,血液溶解控制和患者偏好.
主要成果:
- 77% (克罗瓦利马布) 和67% (埃库利祖马布) 发生了不良事件;没有因AE而停止治疗或死亡.
- 16%的克罗瓦利马布患者经历过渡性免疫复杂反应,这些反应轻度/中度,没有干预就消失了.
- 克罗瓦利马布证明了持续的补充抑制,疾病控制和85%的患者偏好于eculizumab.
结论:
- 克罗瓦利马布在C5抑制剂经验丰富的PNH患者中表现出有利的益处风险概况.
- 皮下施用克罗瓦利马布可能为PNH提供一个不那么繁的治疗选择.
- 结合COMMODORE 2数据,克罗瓦利马布支持PNH管理的新疗法.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...


